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OBJECTIVEdCeliac disease (CD) is associated with type 1 diabetes (T1D). In the current
study, we examined whether CD affects the risk of diabetic retinopathy (DRP) in patients with
T1D.
RESEARCH DESIGN AND METHODSdThis was a population-based cohort study.
Through the Swedish National Patient Register, we identiﬁed 41,566 patients diagnosed with
diabetes in 1964–2009 and who were #30 years of age at diagnosis. CD was deﬁned as having
villous atrophy (Marsh stage 3) according to small intestinal biopsies performed between 1969
and 2008, with biopsy reports obtained from Sweden’s 28 pathology departments. During
follow-up, 947 T1D patients had a diagnosis of CD. We used Cox regression analysis with CD
as a time-dependent covariate to estimate adjusted hazard ratios (aHRs) for DRP in patients with
T1D and CD and compared them with patients with T1D but no CD.
RESULTSdDuration of CD correlated with the risk of DRP.When results were stratiﬁed by time
since CD diagnosis, individuals with T1D andCDwere at a lower risk of DRP in the ﬁrst 5 years after
CD diagnosis (aHR 0.57 [95% CI 0.36–0.91]), followed by a neutral risk in years 5 to ,10 (1.03
[0.68–1.57]). With longer follow-up, coexisting CD was a risk factor for DRP (10 to ,15 years of
follow-up, aHR 2.83 [95% CI 1.95–4.11];$15 years of follow-up, 3.01 [1.43–6.32]).
CONCLUSIONSdHaving a diagnosis of CD for .10 years is a risk factor for the develop-
ment of DRP in T1D. Long-standing CD in patients with T1D merits intense monitoring of DRP.
Diabetes Care 36:316–321, 2013
D iabetic retinopathy (DRP) is a com-monmicrovascular complication ofdiabetes that is characterized by
vascular changes in the retinal circulation
(1). Although the severest form of DRP
leading to blindness is less common, the
rising incidence of T1D means that more
people will develop DRP (2). The major
risk factor for DRP development is hyper-
glycemia (increased HbA1c) (3). Other
risk factors include the duration of diabe-
tes, hypertension, hyperlipidemia, and
nephropathy (3). Some research indicates
that inﬂammatory and autoimmune
mechanisms may be involved in patho-
genesis of DRP (4–7).
Celiac disease (CD) is a common
immune-mediated enteropathy affecting
~1% of the Western population. CD is
associated with other autoimmune disea-
ses, including T1D. The prevalence of CD
in T1D ranges from 3 to 12% (8,9). Al-
though the link between CD and T1D is
well established, few studies have exam-
ined the role of CD in T1D complications
such as DRP. Such studies are warranted to
clarify the need for screening routines in
T1D patients. A recent study (10) address-
ing T1D complications in the presence of
CD found no retinal abnormalities in T1D
patients with CD (10). However, that study
only enrolled 13 patients with CD and
T1D, and there was no follow-up after the
diagnosis of CD (10). We previously
found a higher prevalence of advanced
DRP in patients with T1D and CD than in
T1D control subjects without CD (11), but
that studywas limited in size (T1D andCD:
n = 12), and follow-up ended after 1 year.
Despite its limitations, this study suggests
that microvascular complications may be
more frequent in T1D patients with CD
(11). The aim of this population-based
study was to examine the risk of DRP in
patients with T1D and biopsy-proven CD
versus patients with only T1D.
RESEARCH DESIGN AND
METHODSdIn summary, we linked
T1D and DRP data from the Swedish
National Patient Register (NPR) (12) with
nationwide CD data from small intestinal
biopsy reports.
T1D
Individuals with T1D were identiﬁed by
the Swedish NPR. This register contains
data on inpatient health care since 1964
(nationwide coverage since 1987) and
hospital-based outpatient care since
2001 (12). T1D was deﬁned as having a
relevant ICD code: ICD-7, 260; ICD-8,
250; ICD-9, 250; and ICD-10: E10). In
earlier ICD versions (ICD-7, -8, and -9)
the Swedish NPR did not distinguish be-
tween T1D and type 2 diabetes. Therefore,
in this study, we restricted our study sam-
ple to individuals diagnosed with diabetes
who were#30 years of age. This TID def-
inition has been used before and has a high
positive predictive value (13).
Initially, the Swedish National Board
of Health and Welfare identiﬁed 42,806
individuals with a diagnosis of T1D. The
government agency Statistics Sweden
could conﬁrm the identity of 42,578 of
these individuals. We then excluded 31
individuals because of data irregularities.
Finally, we excluded 981 individuals (2.3%)
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who had a diagnosis of DRP before the ﬁrst
recorded diagnosis of T1D.
Our ﬁnal sample consisted of 41,566
individuals with T1D. Of these, 947
(2.3%) had a diagnosis of CD before 31
December 2009 (hence, 40,619 were not
diagnosed with CD).
CD
CD was deﬁned as duodenal/jejunal vil-
lous atrophy (Marsh stage 3) (14) accord-
ing to biopsy reports from all 28
pathology departments in Sweden. The
biopsies had been performed from 1969
to 2008 (15), but our data collection took
place 2006–2008. We originally had data
on 29,096 individuals with biopsy-
veriﬁed CD (15). Some 95% of individu-
als with villous atrophy have CD (16), and
non-CD diagnoses seldom explain villous
atrophy (0.3% of individuals with villous
atrophy had indications of concomitant
inﬂammatory bowel disease) (16).
Outcome measure
DRP was deﬁned based on relevant ICD
codes in the Swedish NPR (inpatient and
hospital-based outpatient data) (ICD-7,
388.22; ICD-8, 250.02; ICD-9, 250E and
362A; and ICD-10, H36). Severe DRPwas
deﬁned as having a DRP code and re-
quiring retinal laser therapy (surgical
codes 1600, 1637, CKC10, and CKC15).
Statistical analyses and covariates
We used Cox regression analysis with CD
modeled as a time-dependent covariate to
examine the risk of DRP in patients with
T1D and CD versus those with only T1D.
Follow-up began on the date of ﬁrst T1D
diagnosis and ended with the diagnosis of
DRP, emigration, death, or end of the
study period (31 December 2009)d
whichever occurred ﬁrst.
The risk of DRP was evaluated by
years since CD diagnosis (,5 years, 5 to
,10 years, 10 to ,15 years, and $15
years). Other predeﬁned subgroup analy-
ses included stratiﬁcation by sex, calendar
year at T1D diagnosis (1964–1975,
1976–1987, 1988–1999, and 2000–
2009), and age at T1D diagnosis (0–9,
10–19, and 20–30 years). We chose this
age categorization (i.e., 0–9, 10–19, and
20–30 years) because puberty in Swedish
children seldom starts before age 10
years. The risk of DRP in the above sub-
groups was analyzed in two time strata:
,10 years since CD diagnosis and $10
years since CD diagnosis (Table 2). Strat-
iﬁcation for time since CD diagnosis
was deemed necessary because the
proportional hazards assumption was
not fulﬁlled (hence, no overall HR for
DRP in individuals with T1D and CD
was calculated in this study).
The incidence rates (absolute risk) of
DRP in T1D and CD were estimated by
dividing the number of ﬁrst DRP events
with the number of person-years at risk in
the cohort. The number of expected
events was calculated as the number of
observed events divided by the HR. In all
adjusted analyses, the following covari-
ates were considered: age at T1D onset
(three categories), calendar period (four
categories), and sex. In a separate anal-
ysis, we adjusted for country of birth
(Nordic versus non-Nordic country) be-
cause CD (17) and T1D (18) may vary by
geographic origin.
In a ﬁrst sensitivity analysis, we ex-
cluded individuals with a record of oral
antidiabetic medication (ATC codes A10B
+A103) in the prescribed drug register
(19) (such patients may have type 2 dia-
betes even though they have an ICD-10
code consistent with insulin-dependent
diabetes [E10]). In a second analysis, we
excluded women who received their ﬁrst
diagnosis of T1D 0–9 months before giv-
ing birth because these women may have
suffered from gestational diabetes melli-
tus rather than T1D (data on pregnancy
duration were obtained from the Medical
Birth Register [20]). In a third sensitivity
analysis, we restricted study participants
to those with an inpatient diagnosis of
T1D (n = 39,612; 95.3%). We also per-
formed a subanalysis inwhichwe restricted
the outcome to severe DRP requiring reti-
nal laser therapy.
Ethics
This project (2011/841-31/3) was approved
on 15 June 2011 by the ethics review board,
Stockholm, Sweden.
RESULTSdTable 1 shows descriptive
characteristics of the study participants.
DRP risk relative to duration of CD
The risk of DRP correlated with dura-
tion of CD. With adjustment for age, sex,
and calendar period, individuals with
T1D and CD were initially at a lower
risk of DRP during the ﬁrst 5 years after
CD diagnosis (adjusted hazard ratio
[aHR] 0.57), followed by a neutral risk
during years 5 to ,10 (1.03) (Supple-
mentary Table 1). The aHR then in-
creased substantially 10 to ,15 years
after CD diagnosis (2.83), followed by a
threefold increased risk of DRP .15
years after CD diagnosis (3.01) (Supple-
mentary Table 1).
Table 1dCharacteristics of the study participants
T1D and CD T1D P
Total 947 40,619
Age at T1D diagnosis (years)*,a 9 (9) 16 (15) ,0.001
Age at T1D diagnosis (years) ,0.001
0–9 566 (59.8) 11,855 (29.2)
10–19 261 (27.6) 14,347 (35.3)
20–30 120 (12.7) 14,417 (35.5)
Age at end of study (years)* 21 (12) 31 (23) ,0.001
Entry year, median (range) 1997 (1964–2009) 1990 (1964–2009) ,0.001
Follow-up (years)*,b 12 (10) 15 (18) ,0.001
Age at CD diagnosis (years)* 12 (12) No data
Females (%) 522 (55.1) 19,228 (47.3) ,0.001
Males (%) 425 (44.9) 21,391 (52.7) ,0.001
Calendar year ,0.001
1964–1975 96 (10.1) 9,476 (23.3)
1976–1987 150 (15.8) 10,445 (25.7)
1988–1999 342 (36.1) 8,553 (21.1)
2000–2009 359 (37.9) 12,145 (29.9)
Country of birth (Nordic) 940 (99.3) 38,837 (96.0) ,0.001
Gestational diabetes mellitus 14 (1.5) 2,204 (5.4) ,0.001
Oral antidiabetes medication 19 (2.0) 2,336 (5.8) ,0.001
DRP events 102 (10.8) 4,497 (11.1) 0.771
Data are n (%) or *median (interquartile range) unless otherwise indicated. aAges rounded to the nearest year.
bFollow-up time until diagnosis of DRP, death from other cause, emigration, or 31 December 2009
(whichever occurred ﬁrst).
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The absolute risk of DRP during the
ﬁrst 5 years of follow-up in patients with
T1D and CD was 289/100,000 person-
years (compared with 507/100,000 person-
years in the T1D cohort) (excess risk:2218/
100,000 person-years). The absolute risk
increased over time, and after.15 years of
follow-up the absolute risk of DRP was
2,769/100,000 person-years in patients
with T1D and CD versus 920/100,000
person-years in the T1D cohort (excess
risk of 1,849/100,000 person-years) (Sup-
plementary Table 1). Adjusting for country
of birth did not change our risk estimates
(data not shown).
Stratiﬁed analyses
The overall aHR for DRP during the ﬁrst
10 years after CD diagnosis was low
(0.75) (Table 2), and in this time stratum
there were no interactions between CD
and sex, age, or calendar period at T1D
diagnosis (data not shown). Because of a
lack of DRP events in patients with T1D
and CD aged 20–30 years at T1D diagno-
sis, we were unable to calculate a hazard
ratio (HR) in this group (only 120 patients
with T1D and CD had T1D onset between
20 and 30 years of age) (Tables 1 and 2).
The overall aHR for DRP beyond 10
years of CD diagnosis was increased
(2.87) (Table 2), and DRP risks did not
differ according to sex, age, or calendar
period at T1D diagnosis (data not shown).
We were not able to estimate HR for the
last calendar period (2000–2009) because
no study participant had $10 years of
follow-up before the end of the study
(31 December 2009).
Sensitivity analyses
Excluding women who had their ﬁrst
T1D diagnosis during pregnancy (these
women could potentially have gestational
diabetes mellitus) or those with a record
of oral antidiabetes medication did not
inﬂuence theHRs (Supplementary Table 2).
The risk estimate also did not change when
we restricted our dataset to inpatients with
T1D (Supplementary Table 2).
By restricting the outcome to severe
DRP (DRP requiring retinal laser therapy),
we found the same pattern of low initial
risk followed by an increased HR after
10 years with CD (,5 years with CD, HR
0.56 [95% CI 0.18–1.74]; 5–9.99 years,
0.43 [0.11–1.73]; 10–14.99 years, 2.49
[1.18–5.25]; and $15 years, 2.01
[0.50–8.06]).
CONCLUSIONSdIn this large
population-based cohort study, duration
of CD proved to be a strong predictor of
future DRP development. The association
between T1D and CD is well recognized
andmay be due to shared risk factors (21).
Research has largely focused on studying
the prevalence of CD in T1D (8,9), as well
as the beneﬁts of starting a gluten-free diet
in asymptomatic CD within the T1D pop-
ulation (9,22). Few studies have examined
the risk of complications in patients with
both conditions (10,11,23), and none
have thus far been able to determine
time-speciﬁc risks for T1D complications.
The present ﬁndings are consistent
with those of our earlier study (U.K.
study) (11) in which advanced retinopa-
thy was seen in 58.3% of patients with
T1D and CD versus in 25% of patients
with T1D without CD (11). The high
prevalence of DRP, neuropathy, and ne-
phropathy in the U.K. study could mirror
different patient characteristics and T1D-
management traditions in Sweden and
the U.K. Case and control subjects in
the U.K. study were selected from a ter-
tiary diabetes center (possibly with higher
rates of complications because of select-
ing patients with severe T1D), whereas
the current (Swedish) study was based
on all patients with a recorded diagnosis
of T1D. The higher prevalence of DRP in
the U.K. study could also be due to mal-
nutrition in the CD plus T1D group, since
they were thinner than the T1D-only
group.
Research evidence suggests that pa-
tients with T1D screened for CD and
subsequently prescribed a gluten-free diet
improve in their clinical parameters, in-
cluding growth and metabolic control,
compared with T1D patients untreated
for CD (9,22). However, in our U.K. study
on retinopathy a 1-year gluten-free diet
did not inﬂuence the prevalence of reti-
nopathy (11). Although the majority of
young patients with CD seem to adhere
well to a gluten-free diet (24), we cannot
rule out that the addition of yet another
condition (i.e., T1D) affected dietary ad-
herence negatively. In a random subset of
patients with CD in our dataset, 83% ad-
hered to a gluten-free diet (16). In the
current study, we lack individual-based
information on gluten-free diet, but one
can speculate that the highest degree of
dietary adherence was noted just after di-
agnosis, when the risk of DRP is lower.
In a recent multicenter study (25), the
effect of biopsy-proven CD on metabolic
control in patients with T1D was exam-
ined over time. After 5 years of follow-up,
patients with T1D and CD had lower
weight and height than patients with
only T1D (25). However, no differences
in BMI and HbA1c levels were observed
between the groups after the 5-year
follow-up. If patients with T1D and CD
have worse nutritional status than T1D
patients without CD, the former’s risk of
DRP development could be increased
(26).
One explanation for the lower risk of
DRP at baseline in patients with T1D and
CD is the lower levels of cholesterol and
blood pressure found in CD patients (27).
Hypercholesterolemia and hypertension
increase the risk of DRP (3). Recently,
Picarelli et al. (10) demonstrated that pa-
tients with T1D and CD had lower levels
of HbA1c, triglycerides, and cholesterol
than patients with only T1D. These re-
searchers (10) found no signs of retinal
or renal abnormalities in patients with
T1D and CD (10), but the study was cross-
sectional without follow-up.
Inﬂammatory and autoimmune
mechanisms may be involved in DRP de-
velopment (4). In fact, anti-inﬂammatory
drugs have been suggested as potential
new therapies against DRP (7). When
the carotid intima-media thickness was
examined in Italian patients with T1D
and CD (23) (as a measure of subclinical
atherosclerosis), these patients had
greater carotid intima-media thickness
than patients with only T1D (23). The
positive association between CD and sub-
clinical atherosclerosis could signal mi-
crovascular damage (DRP). Patients with
CD are at increased risk of cardiovascular
death (15) and incident ischemic heart
disease (28). Another possible mecha-
nism for the increased risk of DRP seen
over time is that of persistent low-grade
inﬂammation. The intestinal mucosa in
patients with CD can take a long time to
fully recover, even after initiation of a
gluten-free diet. Studies show that chronic,
low-grade inﬂammation plays an impor-
tant role in the pathogenesis of DRP (29).
Having low-grade intestinal inﬂammation
or CD with little symptoms might also
affect the patient’s adherence to a strict
gluten-free diet, which in turn could po-
tentially affect the risk of future DRP.
The pattern of increasing risk of DRP
seen over time was also present in our
subgroup analyses in which we found
lower risk estimates for DRP during ,10
years’ duration of CD diagnosis and
higher risk during $10 years’ CD dura-
tion. The nonsigniﬁcant differences in
DRP risk across calendar periods may be
due to longer T1D duration before the end
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of follow-up in patients diagnosed in earlier
calendar periods (many years at risk for
DRP in each patient). In contrast, patients
diagnosed in the latest calendar period
were (for study design reasons) only at
risk just after T1D diagnosis, and because
the follow-up timewas short, most patients
did not develop DRP. The number of DRP
events after 2000was low,with awide 95%
CI (0.11–1.80). The differences in calendar
period–speciﬁc risk estimates may also re-
ﬂect the changes made in T1D care and
management in Sweden over time as well
as the diagnostic methods used for identi-
ﬁcation of CD.
The major strengths of this study are
the population-based design, the deﬁni-
tion of CD (all cases were biopsy veriﬁed),
and that our study included all patients
with T1D in Sweden. The nationwide
identiﬁcation of CD from all pathology
departments in Sweden (16) minimized
the risk of selection bias. Although we
did not use positive CD serology for the
diagnosis of CD, 88% of those with avail-
able data on CD serology had positive an-
tibodies before biopsy (16). Another
strength is the large number of partici-
pants and statistical power: because
.900 patients had T1D and CD, we
could perform stratiﬁed analyses. Addi-
tional data on pregnancy and medication
allowed us to conduct sensitivity analyses
and minimize potential misclassiﬁcation.
Even when we restricted our outcome to
DRP requiring retinal laser therapy, we
found the same pattern of low HR in early
CD followed by an increased HR over
time (longer duration of CD). Because of
fewer positive events in this subanalysis,
only the HR in patients with CD for 10–
14.99 years was statistically signiﬁcant.
This study is limited by the absence of
information onmetabolic control (HbA1c,
insulin dosage, and BMI) in patients with
T1D. In addition, the 41,566 patients
with T1D were not screened for CD spe-
ciﬁcally for this study; therefore, the clin-
ical presentation may vary among our CD
patients. Today, all Swedish children and
adolescents with T1D are screened for CD
(routine care), but that may not have been
the case in the beginning of the study pe-
riod. In the 1990s, two-thirds (29 of 44)
of all pediatric departments regularly
screened all T1D patients for CD, with
the remaining departments opting for
CD testing on clinical suspicion (30).
Hence, we cannot dismiss the possibility
that there are individuals with undiag-
nosed CD in our T1D-only cohort. Still,
their presence will not affect our risk
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estimate more than marginally because
patients with T1D and undiagnosed CD
are unlikely to make up more than a small
percentage of our reference category (T1D
only). Furthermore, if undiagnosed CD
would have any effect, it would probably
dilute existing associations.
Our results indicate that CD is a
strong predictor for simplex and severe
laser-treated DRP in patients with T1D.
We suggest that the lower effect of DRP in
early CD is due to DRP-protective char-
acteristics of patients with CD (lower
cholesterol and BMI). Long-standing
CD, however, increased the risk of DRP
by .200% (aHR 3.01) and thus merits
closer monitoring of DRP in patients
with T1D.
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